Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients.

Pharmacogenomics - 1 Nov 2012

Rieck Mariana, Schumacher-Schuh Artur F, Altmann Vivian, Francisconi Carolina Lm, Fagundes Paulo Tb, Monte Thaís L, Callegari-Jacques Sidia M, Rieder Carlos Rm, Hutz Mara H

Abstract excerpt

AIM: Dyskinesia and motor fluctuation are frequent and serious complications of chronic levodopa therapy in patients with Parkinson's disease. Since genetic factors could play a role in determining the occurrence of these problems, the aim of the present study was to investigate whether possible functional polymorphisms among DRD2 and ANKK1 genes are associated with the risk of developing dyskinesia and motor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Dyskinesia, Drug-Induced

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Haplotypes

Share to Levodopa

Share to Parkinson Disease

Share to Polymorphism, Genetic

Share to Protein Serine-Threonine Kinases

Share to Receptors, Dopamine D2

Source

Identifiers

PMID: 23171335
DOI: 10.2217/pgs.12.149

Genes

DRD2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients.PMID 23171335Read ↗

The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson's diseaseSemantic proximity Read ↗

The role of genetic factors in the occurrence of levodopa-induced motor complications in Parkinson's disease.Semantic proximity Read ↗

Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson's disease patients?Semantic proximity Read ↗

Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's diseaseSemantic proximity Read ↗

The Role of Single Nucleotide Polymorphisms of Monoamine Oxidase B, Dopamine D2 Receptor, and DOPA Decarboxylase Receptors Among Patients Treated for Parkinson's Disease.Semantic proximity Read ↗

Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa-Induced Dyskinesia in Parkinson's Disease.Semantic proximity Read ↗

Identification of a novel ANKK1 and other dopaminergic (DRD2 and DBH) gene variants in migraine susceptibility.Semantic proximity Read ↗

Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study.Semantic proximity Read ↗

Genetic variation and the risk of haloperidol-related parkinsonism in elderly patients: a candidate gene approach.Semantic proximity Read ↗

Regulatory rare variants of the dopaminergic gene ANKK1 as potential risk factors for Parkinson's disease.Semantic proximity Read ↗

The dopamine D2 receptor gene is a susceptibility locus for Parkinson's disease.Semantic proximity Read ↗

Association of dopamine receptor D3 polymorphism with Levodopa-induced Dyskinesia: A study on Parkinson's disease patients from India.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.